Aussie8 – Lifestyle
Author:
Compass Therapeutics
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
April 24, 2026